380 related articles for article (PubMed ID: 25522000)
21. Solid-State Hydrogen-Deuterium Exchange Mass Spectrometry: Correlation of Deuterium Uptake and Long-Term Stability of Lyophilized Monoclonal Antibody Formulations.
Moorthy BS; Zarraga IE; Kumar L; Walters BT; Goldbach P; Topp EM; Allmendinger A
Mol Pharm; 2018 Jan; 15(1):1-11. PubMed ID: 29182876
[TBL] [Abstract][Full Text] [Related]
22. Impact of controlled ice nucleation on process performance and quality attributes of a lyophilized monoclonal antibody.
Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA; Shah RB
Int J Pharm; 2013 Jun; 450(1-2):70-8. PubMed ID: 23618961
[TBL] [Abstract][Full Text] [Related]
23. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
Nishi H; Mathäs R; Fürst R; Winter G
J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
[TBL] [Abstract][Full Text] [Related]
24. An integrated process analytical technology (PAT) approach to monitoring the effect of supercooling on lyophilization product and process parameters of model monoclonal antibody formulations.
Awotwe Otoo D; Agarabi C; Khan MA
J Pharm Sci; 2014 Jul; 103(7):2042-2052. PubMed ID: 24840395
[TBL] [Abstract][Full Text] [Related]
25. Relevant shaking stress conditions for antibody preformulation development.
Eppler A; Weigandt M; Hanefeld A; Bunjes H
Eur J Pharm Biopharm; 2010 Feb; 74(2):139-47. PubMed ID: 19922795
[TBL] [Abstract][Full Text] [Related]
26. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.
Telikepalli SN; Kumru OS; Kalonia C; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB
J Pharm Sci; 2014 Mar; 103(3):796-809. PubMed ID: 24452866
[TBL] [Abstract][Full Text] [Related]
27. Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies.
Cao W; Krishnan S; Ricci MS; Shih LY; Liu D; Gu JH; Jameel F
Eur J Pharm Biopharm; 2013 Oct; 85(2):287-93. PubMed ID: 23702275
[TBL] [Abstract][Full Text] [Related]
28. Insights into the influence of the cooling profile on the reconstitution times of amorphous lyophilized protein formulations.
Beech KE; Biddlecombe JG; van der Walle CF; Stevens LA; Rigby SP; Burley JC; Allen S
Eur J Pharm Biopharm; 2015 Oct; 96():247-54. PubMed ID: 26253503
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
Gikanga B; Hui A; Maa YF
PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
[TBL] [Abstract][Full Text] [Related]
30. Surface denaturation at solid-void interface--a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures.
Hsu CC; Nguyen HM; Yeung DA; Brooks DA; Koe GS; Bewley TA; Pearlman R
Pharm Res; 1995 Jan; 12(1):69-77. PubMed ID: 7724490
[TBL] [Abstract][Full Text] [Related]
31. Characterization of murine monoclonal antibody to tumor necrosis factor (TNF-MAb) formulation for freeze-drying cycle development.
Ma X; Wang DQ; Bouffard R; MacKenzie A
Pharm Res; 2001 Feb; 18(2):196-202. PubMed ID: 11405291
[TBL] [Abstract][Full Text] [Related]
32. Unexplored benefits of controlled ice nucleation: Lyophilization of a highly concentrated monoclonal antibody solution.
Singh SN; Kumar S; Bondar V; Wang N; Forcino R; Colandene J; Nesta D
Int J Pharm; 2018 Dec; 552(1-2):171-179. PubMed ID: 30261214
[TBL] [Abstract][Full Text] [Related]
33. Effect of temperature ramp rate during the primary drying process on the properties of amorphous-based lyophilized cake, Part 2: Successful lyophilization by adopting a fast ramp rate during primary drying in protein formulations.
Ohori R; Akita T; Yamashita C
Eur J Pharm Biopharm; 2018 Sep; 130():83-95. PubMed ID: 29913271
[TBL] [Abstract][Full Text] [Related]
34. Does controlled nucleation impact the properties and stability of lyophilized monoclonal antibody formulations?
Vollrath I; Friess W; Freitag A; Hawe A; Winter G
Eur J Pharm Biopharm; 2018 Aug; 129():134-144. PubMed ID: 29800618
[TBL] [Abstract][Full Text] [Related]
35. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
Schüle S; Friess W; Bechtold-Peters K; Garidel P
Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
[TBL] [Abstract][Full Text] [Related]
36. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
[TBL] [Abstract][Full Text] [Related]
37. Standardization of the Reconstitution Procedure of Protein Lyophilizates as a Key Parameter to Control Product Stability.
Traub-Hoffmann K; Furtmann B; Laber L; Helm S; Geiger C; Bussemer T
J Pharm Sci; 2020 Jan; 109(1):211-215. PubMed ID: 31655034
[TBL] [Abstract][Full Text] [Related]
38. The stability of lyophilized lipid/DNA complexes during prolonged storage.
Molina Md; Armstrong TK; Zhang Y; Patel MM; Lentz YK; Anchordoquy TJ
J Pharm Sci; 2004 Sep; 93(9):2259-73. PubMed ID: 15295787
[TBL] [Abstract][Full Text] [Related]
39. Shaken, not stirred: mechanical stress testing of an IgG1 antibody.
Kiese S; Papppenberger A; Friess W; Mahler HC
J Pharm Sci; 2008 Oct; 97(10):4347-66. PubMed ID: 18240293
[TBL] [Abstract][Full Text] [Related]
40. Characterization of Protein-Excipient Microheterogeneity in Biopharmaceutical Solid-State Formulations by Confocal Fluorescence Microscopy.
Koshari SH; Ross JL; Nayak PK; Zarraga IE; Rajagopal K; Wagner NJ; Lenhoff AM
Mol Pharm; 2017 Feb; 14(2):546-553. PubMed ID: 28094996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
